Story
Helus Pharma Shares Climb After Completing Enrollment for Phase 3 Depression Drug Trial

Shares of Helus Pharma (NASDAQ:HELP) surged on Tuesday after the company announced it has completed patient enrollment for a pivotal Phase 3 study of its drug candidate HLP003 for Major Depressive Disorder (MDD). The stock climbed by as much as 12.4% on the news, which marks a significant clinical milestone for the company.
Trial Details and Timeline
Helus Pharma confirmed that enrollment for the APPROACH study was completed ahead of schedule, with 223 adults participating. The trial is evaluating HLP003 as a treatment for patients with moderate to severe MDD who have not responded adequately to a stable antidepressant regimen.
Key details of the study include:
- Design: Participants were randomized to receive either a 16 mg dose of HLP003 or a placebo, with two doses administered three weeks apart.
- Primary Endpoint: The main goal is to measure the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) at six weeks after the first dose.
- Next Catalyst: The company expects to release topline data from the APPROACH study in the fourth quarter of 2026.
HLP003 and Market Context
AdHLP003 is a deuterated psilocin analogue that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), a status intended to expedite the development of drugs for serious conditions. The candidate showed promising results in a Phase 2 trial, where it demonstrated a significant reduction in MADRS scores 12 months after dosing.
The market for novel depression treatments is substantial. As a point of reference, Helus noted that Johnson & Johnson reported worldwide sales for its depression treatment, SPRAVATO, of $584 million in the second quarter of 2026, representing a year-over-year increase of 40.8%.
Broader Clinical Program
The APPROACH study is the first of two pivotal trials in Helus Pharma’s PARADIGM Program. Enrollment is ongoing for the second study, named EMBRACE. The company is also conducting a long-term extension study, EXTEND, to evaluate the safety and durability of HLP003 for eligible participants from both pivotal trials.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.